Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (201-210 of 293) with videos related to

Pageof 30
Sort By:
Molecular Cancer Therapeutics|February 20, 2007
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systemsMerrill E Goldsmith, Alian Aguila, Kenneth Steadman, et al.
Cancers|June 10, 2022
A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated CellsAgnes Basseville, Pierre-Christian Violet, Maryam Safari, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2009
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cellsRobert W Robey, Tomasz Obrzut, Suneet Shukla, et al.
Investigative Ophthalmology & Visual Science|September 17, 2021
Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal MelanomaRuchi P Patel, Joanna R Thomas, Katherine M Curt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2016
Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery MattersEden C Payabyab, Sanjeeve Balasubramaniam, Maureen Edgerly, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 29, 2010
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinibMarius Dohse, Christian Scharenberg, Suneet Shukla, et al.
Cancers|October 28, 2023
Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine NeoplasmsMaryam Safari, Luigi Scotto, Thomas Litman, et al.
Cancer Research|July 23, 2003
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transportZhe-Sheng Chen, Robert W Robey, Martin G Belinsky, et al.
Human Gene Therapy|March 28, 2003
Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cellsOlga Ujhelly, Csilla Ozvegy, György Várady, et al.
Cell Cycle (Georgetown, Tex.)|September 9, 2011
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancerVictoria L Luchenko, Crystal D Salcido, Yongwei Zhang, et al.
Pageof 30

Showing results (201-210 of 293) with videos related to

Sort By:
Pageof 30
Molecular Cancer Therapeutics|February 20, 2007
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systemsMerrill E Goldsmith, Alian Aguila, Kenneth Steadman, et al.
Cancers|June 10, 2022
A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated CellsAgnes Basseville, Pierre-Christian Violet, Maryam Safari, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2009
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cellsRobert W Robey, Tomasz Obrzut, Suneet Shukla, et al.
Investigative Ophthalmology & Visual Science|September 17, 2021
Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal MelanomaRuchi P Patel, Joanna R Thomas, Katherine M Curt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2016
Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery MattersEden C Payabyab, Sanjeeve Balasubramaniam, Maureen Edgerly, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 29, 2010
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinibMarius Dohse, Christian Scharenberg, Suneet Shukla, et al.
Cancers|October 28, 2023
Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine NeoplasmsMaryam Safari, Luigi Scotto, Thomas Litman, et al.
Cancer Research|July 23, 2003
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transportZhe-Sheng Chen, Robert W Robey, Martin G Belinsky, et al.
Human Gene Therapy|March 28, 2003
Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cellsOlga Ujhelly, Csilla Ozvegy, György Várady, et al.
Cell Cycle (Georgetown, Tex.)|September 9, 2011
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancerVictoria L Luchenko, Crystal D Salcido, Yongwei Zhang, et al.
Pageof 30